Cargando…

Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression

BACKGROUND: MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. METHODS: Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was si...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuyu, Huo, Wei, Sun, Lidi, Wu, Jie, Zhang, Chengbin, Wang, Huanhuan, Wang, Bin, Wei, Jinlong, Qu, Chao, Cao, Hongshi, Jiang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944991/
https://www.ncbi.nlm.nih.gov/pubmed/33717068
http://dx.doi.org/10.3389/fimmu.2021.590447
Descripción
Sumario:BACKGROUND: MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. METHODS: Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was significantly downregulated in GC. We also confirmed that miR-148b-5p overexpression significantly inhibited GC cell proliferation and invasion in vitro and in vivo. RESULTS: Overexpression of miR-148b-5p not only reprogrammed the metabolic properties of GC but also regulated the immune microenvironment by shifting lymphocyte and myeloid populations. Mechanistically, ATPIF1, an important glycolysis-associated gene, was identified as a direct target of miR-148b-5p and mediated the effect of miR-148b-5p. Notably, the low level of miR-148b-5p was significantly related with poor prognosis of GC patients (P < 0.001). Importantly, the levels of miR-148b-5p significantly changed the sensitivity of GC cells to several anti-cancer drugs (Doxorubicin, P < 0.05, Paclitaxel, P < 0.01, Docetaxel, P < 0.05). CONCLUSIONS: Targeting miR-148b-5p inhibits immunity microenvironment and gastric cancer progression.